Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Short term Debt (2020 - 2021)

Rein Therapeutics (RNTX) has disclosed Short term Debt for 2 consecutive years, with $329000.0 as the latest value for Q1 2021.

  • On a quarterly basis, Short term Debt changed N/A to $329000.0 in Q1 2021 year-over-year; TTM through Mar 2021 was $329000.0, a N/A change, with the full-year FY2020 number at $168000.0, changed N/A from a year prior.
  • Short term Debt was $329000.0 for Q1 2021 at Rein Therapeutics, up from $168000.0 in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $329000.0 in Q1 2021 to a low of $48000.0 in Q3 2020.